Kalytera Announces Binding Agreement to Acquire Salzman Group
Hit enter to search or ESC to close
Investors
Investor Overview
Press Releases
Company Information
SEDAR Filings
SEC Filings
Stock Information
Corporate Governance
Contact
Investors
Investor Overview
Press Releases
Company Information
SEDAR Filings
SEC Filings
Stock Information
Corporate Governance
Contact
Press Releases
Menu
Overview
Press Releases
Company Information
Stock Information
Sedar Filings
Corporate Governance
Recent Press Releases
Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants, and Provides Corporate Update
August 7, 2020
Kalytera Announces Escrowed Closing of Private Placement of Common Shares and Common Share Purchase Warrants
July 24, 2020
Kalytera Announces Exclusive License Agreement with Salzman Group for Development and Commercialization of R-107 for Treatment of Coronavirus and COVID-19 Infection
July 16, 2020
Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants
July 15, 2020
Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company’s Private Placement
June 30, 2020
Kalytera Provides Update Regarding Acquisition of Salzman Group
June 16, 2020
Kalytera Announces Data Demonstrating that R-107 Prevents Tissue Damage and Increases Survival in a Murine Study of Chlorine Inhalational Lung Injury
June 15, 2020
View all News and Insights
Browse by Year
2020
2019
2018
2017
2016
2015
Kalytera Announces Binding Agreement to Acquire Salzman Group
Investors
Investor Overview
Press Releases
Company Information
SEDAR Filings
SEC Filings
Stock Information
Corporate Governance
Contact
© 2016 Kalytera Therapeutics, Inc.
